X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs LUPIN LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES LUPIN LTD PIRAMAL ENTERPRISES/
LUPIN LTD
 
P/E (TTM) x 37.6 16.6 226.9% View Chart
P/BV x 3.7 3.9 97.0% View Chart
Dividend Yield % 0.6 0.8 81.3%  

Financials

 PIRAMAL ENTERPRISES   LUPIN LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
LUPIN LTD
Mar-16
PIRAMAL ENTERPRISES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,0652,127 50.1%   
Low Rs8051,294 62.2%   
Sales per share (Unadj.) Rs383.0304.1 126.0%  
Earnings per share (Unadj.) Rs55.150.4 109.3%  
Cash flow per share (Unadj.) Rs74.160.7 122.1%  
Dividends per share (Unadj.) Rs17.507.50 233.3%  
Dividend yield (eoy) %1.90.4 426.9%  
Book value per share (Unadj.) Rs719.9243.8 295.3%  
Shares outstanding (eoy) m172.56450.58 38.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.45.6 43.4%   
Avg P/E ratio x17.033.9 50.0%  
P/CF ratio (eoy) x12.628.2 44.8%  
Price / Book Value ratio x1.37.0 18.5%  
Dividend payout %31.814.9 213.5%   
Avg Mkt Cap Rs m161,344770,740 20.9%   
No. of employees `0003.816.4 23.1%   
Total wages/salary Rs m16,89821,077 80.2%   
Avg. sales/employee Rs Th17,472.68,379.6 208.5%   
Avg. wages/employee Rs Th4,466.91,289.0 346.5%   
Avg. net profit/employee Rs Th2,512.81,388.7 180.9%   
INCOME DATA
Net Sales Rs m66,099137,016 48.2%  
Other income Rs m2,4251,877 129.2%   
Total revenues Rs m68,524138,893 49.3%   
Gross profit Rs m18,72337,535 49.9%  
Depreciation Rs m3,2744,635 70.6%   
Interest Rs m9,388446 2,103.9%   
Profit before tax Rs m8,48534,330 24.7%   
Minority Interest Rs m3-88 -3.8%   
Prior Period Items Rs m1,5930-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,03211,536 8.9%   
Profit after tax Rs m9,50622,707 41.9%  
Gross profit margin %28.327.4 103.4%  
Effective tax rate %12.233.6 36.2%   
Net profit margin %14.416.6 86.8%  
BALANCE SHEET DATA
Current assets Rs m47,48897,790 48.6%   
Current liabilities Rs m104,36253,872 193.7%   
Net working cap to sales %-86.032.1 -268.4%  
Current ratio x0.51.8 25.1%  
Inventory Days Days4185 48.0%  
Debtors Days Days51121 42.2%  
Net fixed assets Rs m26,53286,379 30.7%   
Share capital Rs m345901 38.3%   
"Free" reserves Rs m114,024105,735 107.8%   
Net worth Rs m124,221109,844 113.1%   
Long term debt Rs m75,81253,739 141.1%   
Total assets Rs m308,356224,378 137.4%  
Interest coverage x1.977.9 2.4%   
Debt to equity ratio x0.60.5 124.7%  
Sales to assets ratio x0.20.6 35.1%   
Return on assets %6.110.3 59.4%  
Return on equity %7.720.7 37.0%  
Return on capital %10.021.2 47.0%  
Exports to sales %17.249.1 35.0%   
Imports to sales %6.67.4 88.7%   
Exports (fob) Rs m11,36267,244 16.9%   
Imports (cif) Rs m4,36410,199 42.8%   
Fx inflow Rs m14,43571,405 20.2%   
Fx outflow Rs m5,18317,807 29.1%   
Net fx Rs m9,25353,598 17.3%   
CASH FLOW
From Operations Rs m-67,773-3,690 1,836.8%  
From Investments Rs m-8,768-69,434 12.6%  
From Financial Activity Rs m76,19958,126 131.1%  
Net Cashflow Rs m-342-14,998 2.3%  

Share Holding

Indian Promoters % 52.9 46.6 113.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.0 11.3 35.4%  
FIIs % 26.6 31.9 83.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.1 163.4%  
Shareholders   93,274 98,259 94.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 18, 2017 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS